GPN Vaccines raises AU$ 7 million in oversubscribed funding
30 Jun 2020 GPN Vaccines closes A$7 million Series A2 round oversubscribed with Forepont Capital Partners becoming a significant investor Adelaide, Australia, 30th June 2020 – Australian biotechnology company GPN Vaccines, which is developing a vaccine against the world’s foremost bacterial pathogen, Streptococcus pneumoniae, is pleased to announce it has raised A$7 million
